Ganetespib (STA-9090)

製品コードS1159

Ganetespib (STA-9090)化学構造

分子量(MW):364.4

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

サイズ 価格(税別)  
JPY 50132.00
JPY 44820.00
JPY 61420.00

カスタマーフィードバック(3)

  • Loss of viability (Z score) resulting from HSP90 inhibition (HSP90i; ganetespib, 5 nM) in FANCA null GM6914 cells transduced with retroviruses encoding FANCA wild-type (squares; WT) or empty vector control (circles; null) in the presence (black symbols) of MMC (31.6 nM) or DMSO control (gray symbols). Data from three independent experiments are presented as mean ± SEM.

    Cell, 2017, 168(5):856-866. Ganetespib (STA-9090) purchased from Selleck.

    Breast cancer (MDA-MB-231), pancreatic cancer (PaTu2), lung cancer (A549), colon cancer HCT-116, and acute myeloid leukemia (SKM1) cell lines were incubated with increasing amounts of PU-H71 and STA-9090 as indicated. Western blot analysis with PRKD2, cleaved PARP, and cleaved caspase-9 antibodies is depicted.

    Cancer Res 2014 10.1158/0008-5472.CAN-14-1017. Ganetespib (STA-9090) purchased from Selleck.

  • Western blot analysis of the expression of Brd4 and Hsp90 from whole-cell lysates of Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 at indicated concentrations for 24 h (B), and in Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 (200 nM) at indicated time points (C).

    Hum Mol Genet, 2015, 10.1093/hmg/ddv136. Ganetespib (STA-9090) purchased from Selleck.

製品安全説明書

HSP (e.g. HSP90)阻害剤の選択性比較

生物活性

製品説明 Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
ターゲット
HSP90 [1]
(OSA 8 cells)
4 nM
体外試験

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL60 MUXBdI9xfG:|aYOgRZN{[Xl? MmrON|AwQDBxMUWwM|I2OCCwTR?= MoL0NlQwPDhxN{KgbC=> NVvkUlk2cW6mdXPld{Bld3OnIHTldIVv\GGwdDDpcoR2[3Srb36gc4Yh[XCxcITvd4l{ M4TGUFI2QDh{NUWw
MV411 M4XmbmFxd3C2b4Ppd{BCe3OjeR?= M1LqeVMxNzhyL{G1NE8zPTBibl2= MnT4NlQwPDhxN{KgbC=> MYXpcoR2[2W|IHTvd4Uh\GWyZX7kZY51KGmwZIXjeIlwdiCxZjDhdI9xfG:|aYO= NV;uWHptOjV6OEK1OVA>
MGC-803 MmrnR4VtdCCYaXHibYxqfHliQYPzZZk> NHjE[lkxNjFvMUCwNEBvVQ>? M{XpVlczKGh? NInENYlqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 Mn63NlU2QTB6MEW=
SGC-7901 MWnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVSwMlEuOTByMDDuUS=> MUi3NkBp MVfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MXOyOVU6ODhyNR?=
MKN-28 NVXUNW9tS2WubDDWbYFjcWyrdImgRZN{[Xl? MlrINE4yNTFyMECgcm0> M1i1[|czKGh? M{XmZolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MYWyOVU6ODhyNR?=
MGC-803 M2TFSWZ2dmO2aX;uJGF{e2G7 NEGzZnQxNjFvMUCwNEBvVQ>? NWrjbGRqOjRiaB?= NUXQ[IhpcW6mdXPld{BIOi:PIHPlcIwu[3mlbHWgZZJz\XO2 M2jGV|I2PTlyOEC1
HCT-116 M4TVZmZ2dmO2aX;uJGF{e2G7 NIrCXXc2OG6P NYPSdnloOjRiaB?= MV\EUXNQ MUTpcoR2[2WmIFewM2cyKGG{cnXzeC=> NY\tTFVYOjV{MUC3PVQ>
HT-29 Mnf2SpVv[3Srb36gRZN{[Xl? NVHpZotWPTCwTR?= NV;4S4tEOjRiaB?= NVKxXotFTE2VTx?= M2SyZYlv\HWlZXSgS|AwTzFiYYLy[ZN1 MoLUNlUzOTB5OUS=
SCC25 NYjEcFE1S3m2b4jpZ4l1gSCDc4PhfS=> NYDNUVJmOTBxNUCgcm0> NFe3fHIzPCCq MU\k[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm= M2Tvd|I2OjB3NEOw
FUDA MX;DfZRwgGmlaYT5JGF{e2G7 NF\xeVEyOC93MDDuUS=> M{TwUFI1KGh? M163eoRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDk[ZBmdmSnboTsfS=> NF;ZWYszPTJyNUSzNC=>
Detroit562 NF\F[G5EgXSxeHnjbZR6KEG|c3H5 NH;zPYgyOC93MDDuUS=> MV6yOEBp NIrJ[HNl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> M4TxdlI2OjB3NEOw
CAL27 Mke3R5l1d3irY3n0fUBCe3OjeR?= NHzNTVAyOC93MDDuUS=> MXSyOEBp MkX6[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5 M3TGfVI2OjB3NEOw
DSH1 NVPuUXJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHoUm5NUUN3ME22JI5O MW[yOFc5PDh|OR?=
SW-1710 NUjkRlF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPnXoluUUN3ME22JI5O M2XZc|I1Pzh2OEO5
T24 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;TXoFEUUN3ME23JI5O M3HOR|I1Pzh2OEO5
RT112 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTlibl2= M{fqPVI1Pzh2OEO5
639-V MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnjNGEyUUN3ME2xNEBvVQ>? MYOyOFc5PDh|OR?=
SCaBER Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrSTWM2OD1zMDDuUS=> M4XsfFI1Pzh2OEO5
BFTC M3\Yfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7FTWM2OD1zNzDuUS=> M1G2PVI1Pzh2OEO5
J82 NU\uWXpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;Rc2lEPTB;MUigcm0> MlGzNlQ4QDR6M{m=
HT-1376 NY\IcFdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[1fGlEPTB;MkGgcm0> Mnq2NlQ4QDR6M{m=
647-V MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki1TWM2OD1{NzDuUS=> NGLrVFAzPDd6NEizPS=>
UM-UC3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\YfId6UUN3ME2zN{BvVQ>? Mlf1NlQ4QDR6M{m=
LB831-BLC NH7tZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTN2IH7N Mo\yNlQ4QDR6M{m=
KU-19-19 M{m3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK3TWM2OD1|NjDuUS=> NEPjN3MzPDd6NEizPS=>
35612 NUjWTI9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT3TWM2OD1|ODDuUS=> M{DJelI1Pzh2OEO5
5637 NICyWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXpR5ZYUUN3ME20OEBvVQ>? MWOyOFc5PDh|OR?=
HT-1197 M1Swdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v0UGlEPTB;NUOgcm0> MlrYNlQ4QDR6M{m=
MGH-U3 M3\EWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nMN2lEPTB;NUOgcm0> NXrKOYNzOjR5OES4N|k>
TCCSUP NVrXeWNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF2MjDuUS=> MX[yOFc5PDh|OR?=
RT4 M1fKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF5M{Ogcm0> M3rEXFI1Pzh2OEO5
SW780 MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjLblZKSzVyPUO0OVEhdk1? MVqyOFc5PDh|OR?=
RKO M{DNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjNTWM2OD12IH7N NHjD[5kzPDZ6Mke0Oy=>
LS-411 N M2Lad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3nc2N7UUN3ME21JI5O Mk\JNlQ3QDJ5NEe=
SW620 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjQcpJKSzVyPUigcm0> MoKxNlQ3QDJ5NEe=
HCT-15 MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17HNGlEPTB;ODDuUS=> MmXrNlQ3QDJ5NEe=
HuTu-80 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\5VG5lUUN3ME2xN{BvVQ>? NGDZdZQzPDZ6Mke0Oy=>
HCT 116 NVe1O5I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF2IH7N M2K0dVI1Pjh{N{S3
COLO-205 MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DYXWlEPTB;MUSgcm0> MWWyOFY5Ojd2Nx?=
NCI-H747 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjzXHo4UUN3ME2xO{BvVQ>? MWiyOFY5Ojd2Nx?=
COLO-678 MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Hz[WlEPTB;MkGgcm0> MX:yOFY5Ojd2Nx?=
LoVo MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ{IH7N MYiyOFY5Ojd2Nx?=
LS-1034 NUe5U|FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXOXXhKSzVyPUOxJI5O MYCyOFY5Ojd2Nx?=
SNU-C2B MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTR3IH7N MoDBNlQ3QDJ5NEe=
LS-123 M{\iNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm0TWM2OD15MzDuUS=> MoT3NlQ3QDJ5NEe=
SK-CO-1 NH24fZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRThzIH7N NYXqSHhxOjR4OEK3OFc>
HCC2998 NHjLPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF{ODDuUS=> NIrNPHQzPDZ6Mke0Oy=>
MDA-MB-231 MlG4SpVv[3Srb36gRZN{[Xl? NInye5QyODBibl2= M{LyelMxKG2rbh?= M33NeYlvcGmkaYTzJIFk[3WvdXzheIlwdiCxZjDITWYuOc7z Ml;ENlQzPDh{NkW=
MDA-MB-435 M3vuTmZ2dmO2aX;uJGF{e2G7 NGWyUHYyODBibl2= NIrRV4U{OCCvaX6= MUjpcohq[mm2czDhZ4N2dXWuYYTpc44hd2ZiSFnGMVHPuQ>? M1jOdlI1OjR6Mk[1
BT-20  M3PUfGZ2dmO2aX;uJGF{e2G7 M4f6c|ExOC9{NUCgcm0> MlPXNlQhcA>? M4\JPJJme3WudHXkJIlvKGFiZH;z[U1l\XCnbnTlcpQh\GW|dHHibYxqgmG2aX;uJI9nKEWJRmKsJGlITi2LUjygUWVVNCCjbnSgR3JCTg>? NGLmfHkzPDF5M{W0NS=>
MDA-MB-231 MlrlSpVv[3Srb36gRZN{[Xl? MXKxNFAhdk1? NUT1WXJ1OjRiaB?= NGWyUIVqdmirYnn0d{B1cGVibXnndoF1d3K7IHHu[EBqdn[jc3n2[UBk[XCjY3n0feKh NUPtTpZSOjRzN{O1OFE>
H82 MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPoTWM2OD1|MD6yO{BvVQ>? NFe2WowzPDF4NkWwOS=>
GLC4 NYXLR2pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3kVG9FUUN3ME2yNE41PyCwTR?= MkjPNlQyPjZ3MEW=
H69 M3\4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTh|LkO2JI5O NHLWVmkzPDF4NkWwOS=>
H128 M3PqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TiTGlEPTB;NkmuOVUhdk1? MoPHNlQyPjZ3MEW=
H146 MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnTO2xKSzVyPUK4MlUyKG6P NXW2VXg1OjRzNk[1NFU>
H187 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfvW2RxUUN3ME2yOE46QSCwTR?= M2fVTVI1OTZ4NUC1
H526 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPwNG1KSzVyPUKxMlY1KG6P NEDpSXYzPDF4NkWwOS=>
N592 M2T2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\JXGlEPTB;MUSuNVIhdk1? M1XE[|I1OTZ4NUC1
H620 MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq4[2kyUUN3ME2zNk43PyCwTR?= NIXNUGgzPDF4NkWwOS=>
H792 MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\rNGlEPTB;NEWuNFchdk1? NX\YdVNzOjRzNk[1NFU>
H1173 M3HTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrFNZJmUUN3ME2xNk43OiCwTR?= MmTkNlQyPjZ3MEW=
AC3 M2LNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmGyTWM2OD1{NT65JI5O NV7qSoNDOjRzNk[1NFU>
H82 MoL6SpVv[3Srb36gRZN{[Xl? MoPaN|Ahdk1? NH3oeVE4OiCq NH6zRmxqdmS3Y3XzJJBmenOrc4TlcpQhTzJxTTDwbIF{\SCjcoLld5Q> M1qzUFI1OTZ4NUC1
GLC4 M{TBbWZ2dmO2aX;uJGF{e2G7 M1jDSlMxKG6P NHPCdFA4OiCq M2DYXIlv\HWlZYOgdIVze2m|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=> M{Phe|I1OTZ4NUC1
H146  M4jMZ2Z2dmO2aX;uJGF{e2G7 MlLkN|Ahdk1? NXPhS2ZKPzJiaB?= MVnpcoR2[2W|IIDldpNqe3SnboSgS|IwVSCyaHHz[UBienKnc4S= NFjNcIozPDF4NkWwOS=>
OVCAR-5 MnjyR4VtdCCYaXHibYxqfHliQYPzZZk> NH7VPJoxNTFyMECgcm0> NFfQXWM4OiCq NUTEWXozcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MX[yN|kxODF|Nh?=
OVCAR-8 MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFn0cIoxNTFyMECgcm0> M4fSOVczKGh? NXm4cYFocW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NF6xbmwzOzlyMEGzOi=>
A1847 NYfrUIVqS2WubDDWbYFjcWyrdImgRZN{[Xl? MVSwMVExODBibl2= M125cVczKGh? MX;pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M3rZO|I{QTByMUO2
SKOV-3 MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHjiXXgxNTFyMECgcm0> NEPBfmY4OiCq M1v0SYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NH3kZ2kzOzlyMEGzOi=>
OVCAR-5 NGXZ[4JCeG:ydH;zbZMhSXO|YYm= MlLiNVAuOTByIH7N Ml7TNlQwPDhxN{KgbC=> MXPpcoR2[2W|IHHwc5B1d3OrczD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfGy7 NGDSTJozOzlyMEGzOi=>
OVCAR-8 MXnBdI9xfG:|aYOgRZN{[Xl? NEjnNJcyOC1zMECgcm0> NYr1WXFuOjRxNEivO|IhcA>? NVH2bXRDcW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboTsfS=> NF[5NGEzOzlyMEGzOi=>
A1847 MUPBdI9xfG:|aYOgRZN{[Xl? MUixNE0yODBibl2= NUewVHdtOjRxNEivO|IhcA>? NIDqeXdqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHHu[EBld3OnIHTldIVv\GWwdHz5 NFjJepozOzlyMEGzOi=>
H2228 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXiwMVExODBibl2= M2nBNlczKGh? NI[4b25KSzVyPUGzJI5O MU[yN|U{OzJ4NR?=
H3122 NFG3NGVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYrYZlZ2OC1zMECwJI5O MYC3NkBp MofDTWM2OD1zMDDuUS=> MkC5NlM2OzN{NkW=
K008 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYXjO3FbUUN3ME22NEBvVQ>? NI\kOGMzOzRzOEWyNy=>
K028 M{mwZmNmdGxiVnnhZoltcXS7IFHzd4F6 M2TkUWlEPTB;OESgcm0> NV3BU3dUOjN2MUi1NlM>
K029 NUXjVHNQS2WubDDWbYFjcWyrdImgRZN{[Xl? NUO3RpZ7UUN3ME20OkBvVQ>? NUDPVnY4OjN2MUi1NlM>
M23 MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3PhUWlEPTB;M{euOUBvVQ>? NVPTWnY4OjN2MUi1NlM>
K033 NELLWpFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2i4SmlEPTB;N{WuOUBvVQ>? NITwN2szOzRzOEWyNy=>
K008 NUS5dHFkTnWwY4Tpc44hSXO|YYm= MWmyOVAhdk1? NIPteIszPCCq M1;LVIlv\HWlZYOgS|Ih[XK{ZYP0 NXvKU3R6OjN2MUi1NlM>
K028 MonBSpVv[3Srb36gRZN{[Xl? NWmx[ZhbOjVyIH7N MoPrNlQhcA>? M{TMU4lv\HWlZYOgS|Ih[XK{ZYP0 M3i5T|I{PDF6NUKz
K029 Ml\rSpVv[3Srb36gRZN{[Xl? MmDCNlUxKG6P NUPSb|lnOjRiaB?= MXXpcoR2[2W|IFexJIFzemW|dB?= MUiyN|QyQDV{Mx?=
M23 NFjOXlJHfW6ldHnvckBCe3OjeR?= M2rncVI2OCCwTR?= NUnVXnJIOjRiaB?= NHTZTHNqdmS3Y3XzJGcyKGGwZDDHNk9OKGG{cnXzeC=> NF\LZYYzOzRzOEWyNy=>
K033 NFzFfHJHfW6ldHnvckBCe3OjeR?= MmDZNlUxKG6P NFiwSnczPCCq NUDBRoJocW6mdXPld{BiKG2xZHXzeEBqdmO{ZXHz[UBqdiCJMTDwc5B2dGG2aX;u MkTqNlM1OTh3MkO=
K008 NHe2d2FCeG:ydH;zbZMhSXO|YYm= M{n1TFExOCCwTR?= NYHTR5BnPzJiaB?= MnjTd4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>? MUmyN|QyQDV{Mx?=
K028 Mn21RZBweHSxc3nzJGF{e2G7 NXLPSpc3OTByIH7N M3PRdFczKGh? Mn;Qd4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>? NUSweJZbOjN2MUi1NlM>
K029 M1TYTGFxd3C2b4Ppd{BCe3OjeR?= M2XnVFExOCCwTR?= M1jZclczKGh? NYP5c|FKe2mpbnnmbYNidnSueTDpcoR2[2W|IHHwc5B1d3Orcx?= Mk\SNlM1OTh3MkO=
M23 NXLvZYtNSXCxcITvd4l{KEG|c3H5 MWixNFAhdk1? MW[3NkBp NGXMVmd{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| NGTz[5UzOzRzOEWyNy=>
K033 M1vMZWFxd3C2b4Ppd{BCe3OjeR?= MljqNVAxKG6P MkX4O|IhcA>? M1ewTpNq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN? M4T4NlI{PDF6NUKz
RD M3rMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRThibl2= MniwNlM{ODN5NEG=
Rh41 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFyLkSgcm0> M3XlTFI{OzB|N{Sx
Rh18 NX;NUlZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjTTZdKSzVyPU[uNkBvVQ>? NXjKXZU2OjN|MEO3OFE>
Rh30 NID4d4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTVwNjDuUS=> MojsNlM{ODN5NEG=
BT-12 NULBRVRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n2[2lEPTB;MUSuN{BvVQ>? M4HE[lI{OzB|N{Sx
CHLA-266 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJ5LkGgcm0> NFy0bHkzOzNyM{e0NS=>
TC-71 NG\1ZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTRwNTDuUS=> NFTi[ZYzOzNyM{e0NS=>
CHLA-9 NVXMNIQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLlW|dKSzVyPUSuOkBvVQ>? MX6yN|MxOzd2MR?=
CHLA-10 MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n2fmlEPTB;NT63JI5O MWGyN|MxOzd2MR?=
CHLA-258 NX7YfppbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTZwNDDuUS=> NIHDbW0zOzNyM{e0NS=>
SJ-GBM2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnToTWM2OD1zMj65JI5O NEDrVIkzOzNyM{e0NS=>
NB-1643 NYPQPW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTdwNDDuUS=> Mo\vNlM{ODN5NEG=
NB-EBc1 NEPjfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\vS4Z[UUN3ME2xOk45KG6P MYqyN|MxOzd2MR?=
CHLA-90 NYK1OWs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PGU2lEPTB;MkKuN{BvVQ>? NYDIeHNzOjN|MEO3OFE>
CHLA-136 M2XNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ|LkKgcm0> NHzKXXgzOzNyM{e0NS=>
NALM-6 M2X2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH6[4l2UUN3ME2xNU44KG6P NILwUFgzOzNyM{e0NS=>
COG-LL-317 NYPJSFd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXu[m9KSzVyPUSuOEBvVQ>? MlvwNlM{ODN5NEG=
RS4;11 MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m2UmlEPTB;MUOuOUBvVQ>? NF\LXIgzOzNyM{e0NS=>
MOLT-4 MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jlS2lEPTB;MUCuOkBvVQ>? NWfkNFJnOjN|MEO3OFE>
CCRF-CEM (1) NYTp[YVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XkfWlEPTB;MUKuOUBvVQ>? MnnVNlM{ODN5NEG=
CCRF-CEM (2) NIfJVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm1TIZ4UUN3ME23MlIhdk1? NFLWTVYzOzNyM{e0NS=>
Kasumi-1 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLVTWM2OD13Lkigcm0> MVSyN|MxOzd2MR?=
Karpas-299 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTlwNjDuUS=> MlvINlM{ODN5NEG=
Ramos-RA1 NEHETXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTZTWM2OD15LkSgcm0> MVKyN|MxOzd2MR?=
LNCaP NWnwc3U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES4bVNKSzVyPUigcm0> Mm\LNlMyPTJyMES=
VCaP MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH5cod5UUN3ME23JI5O NEC4WHczOzF3MkCwOC=>
H1355 M{LHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\DTWM2OD13IH7N M1r0OFI{ODF{MkS4
H157 MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3vbXRKSzVyPUegcm0> NXn0XWltOjNyMUKyOFg>
H460 M{O4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrtNGJsUUN3ME24JI5O MX[yN|AyOjJ2OB?=
IA-LM MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j4fmlEPTB;MUCgcm0> NYO4WHY5OjNyMUKyOFg>
HOP-62 NYX0WZpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTJPJFJUUN3ME2xNUBvVQ>? MUKyN|AyOjJ2OB?=
H23 NX\BWGx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHWwW5hKSzVyPUGxJI5O M2foZlI{ODF{MkS4
H2030 MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDqbY9KSzVyPUGyJI5O NVLpfGtVOjNyMUKyOFg>
H441 NV22[VlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzQU21KSzVyPUG0JI5O MUiyN|AyOjJ2OB?=
H2212 NGS1[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWmxe2lLUUN3ME2xO{BvVQ>? MmLBNlMxOTJ{NEi=
SK-LU-1 M1v2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\jTWM2OD1zODDuUS=> M3\0cFI{ODF{MkS4
H2009 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{SwPGlEPTB;MUmgcm0> Mn3xNlMxOTJ{NEi=
H1792 NWH4S|NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H4SmlEPTB;MkCgcm0> M1\Q[FI{ODF{MkS4
COR-L23 NXGwcmd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrqdZhKSzVyPUKyJI5O M2PaOFI{ODF{MkS4
H727 M4KxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjvTWM2OD1{ODDuUS=> NV;vVFJzOjNyMUKyOFg>
H1734 NGPF[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJ6IH7N MnHyNlMxOTJ{NEi=
H358 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDMTWM2OD1{OTDuUS=> M2m4dlI{ODF{MkS4
A549 M2LNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTR|IH7N MlOxNlMxOTJ{NEi=
H2122 M1zFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XEZ2lEPTB;NUOgcm0> NWK1[YNrOjNyMUKyOFg>
Calu-1 NVvjVHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\6VIdKSzVyPUW4JI5O M{noS|I{ODF{MkS4
Calu-6 M4DuT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r3eWlEPTB;NkSgcm0> Mo\UNlMxOTJ{NEi=
NCI-H1975 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDpe5YxPDhiaB?= NWrUVW1qUUN3ME2xOkBvVQ>? M{HKNVIzOTR2Nk[1
NCI-H1975 NWfaVo02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUW3NkBp M1S4OWlEPTB;ODDuUS=> NHHtdnQzOjF2NE[2OS=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]

お薦めの試験操作(参考用のみ)

細胞試験: [1]
+ 展開
  • 細胞株: OSA cells
  • 濃度: 0.001-1μM
  • 反応時間: 5 days
  • 実験の流れ: A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
    (参考用のみ)
動物試験:[4]
+ 展開
  • 動物モデル: Female severe combined immune-deficient (SCID) mice
  • 製剤: In DMSO and diluted 1:10 with 20% Cremophor RH 40
  • 投薬量: 25 mg/kg/day for 3 days
  • 投与方法: Tail vein injection
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 40 mg/mL (109.76 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+45% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
11mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 364.4
化学式

C20H20N4O3

CAS No. 888216-25-9
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03783949 Recruiting Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma Universitaire Ziekenhuizen Leuven|European Commission November 30 2018 Phase 2
NCT03783949 Recruiting Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma Universitaire Ziekenhuizen Leuven|European Commission November 30 2018 Phase 2
NCT02637375 Withdrawn Breast Cancer University of Chicago May 2016 Not Applicable
NCT02637375 Withdrawn Breast Cancer University of Chicago May 2016 Not Applicable
NCT02389751 Active not recruiting Gastroesophageal Junction Adenocarcinoma|Malignant Neoplasm of the Cervical Esophagus|Malignant Neoplasm of the Thoracic Esophagus|Stage IIA Esophageal Cancer AJCC v7|Stage IIB Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7|Stage IIIC Esophageal Cancer AJCC v7 M.D. Anderson Cancer Center|National Cancer Institute (NCI) April 10 2015 Phase 1
NCT02389751 Active not recruiting Gastroesophageal Junction Adenocarcinoma|Malignant Neoplasm of the Cervical Esophagus|Malignant Neoplasm of the Thoracic Esophagus|Stage IIA Esophageal Cancer AJCC v7|Stage IIB Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7|Stage IIIC Esophageal Cancer AJCC v7 M.D. Anderson Cancer Center|National Cancer Institute (NCI) April 10 2015 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Does this inhibitor inhibit both isoforms of HSP90?

  • 回答:

    We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

HSP (e.g. HSP90)シグナル伝達経路

HSP (e.g. HSP90) Inhibitors with Unique Features

相関HSP (e.g. HSP90)製品

Tags: Ganetespib (STA-9090)を買う | Ganetespib (STA-9090) ic50 | Ganetespib (STA-9090)供給者 | Ganetespib (STA-9090)を購入する | Ganetespib (STA-9090)費用 | Ganetespib (STA-9090)生産者 | オーダーGanetespib (STA-9090) | Ganetespib (STA-9090)化学構造 | Ganetespib (STA-9090)分子量 | Ganetespib (STA-9090)代理店
×

大阪市内で「G20サミット」が開催されることに伴い、大阪府内で大規模な交通規制が行われる影響で、6月26日(水)から7月1日(月)までの間、下記地域へ出荷が行えなくなります。
対象地域
大阪府(全域)、兵庫県(芦屋市、尼崎市、伊丹市、西宮市)
上記地域より西の地域につきましては納期の遅延が予想されます。
また、国際便も遅延が予想されているため国内在庫がない製品の納期が一週間程度遅れる可能性がございます。
ご不便をおかけいたしますが、宜しくお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID